Peabody Energy reviewing options related to deal with Anglo American-May 2024-www.financetom.com

Peabody Energy reviewing options related to deal with Anglo American

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Peabody Energy reviewing options related to deal with Anglo American

Apr 8, 2025 2:36 PM

April 8 (Reuters) - Peabody Energy ( BTU ) said on

Tuesday it was reviewing all options related to its $3.78

billion potential acquisition of steelmaking coal assets from

Anglo American.

(Reporting by Vallari Srivastava in Bengaluru; Editing by

Shinjini Ganguli)

Previous page： E3 Lithium Narrows Q1 Loss; Company Hasn't Started Commercial Production or Generated Cash Flow Next page： --Cato Keeps Quarterly Dividend at $0.17 per share, Payable June 24 to Shareholders of Record June 10

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

E3 Lithium Narrows Q1 Loss; Company Hasn't Started Commercial Production or Generated Cash Flow

May 24, 2024

08:25 AM EDT, 05/24/2024 (MT Newswires) -- E3 Lithium ( EEMMF ) on Friday reported a narrower loss for the first quarter even though the company has not generated revenues from operations and had an accumulated deficit of $45.2 million at the end of March. The company reported a first-quarter net loss of $2.4 million, or $0.03 per share, compared...

--Cato Keeps Quarterly Dividend at $0.17 per share, Payable June 24 to Shareholders of Record June 10

May 24, 2024

08:17 AM EDT, 05/24/2024 (MT Newswires) -- Price: 5.73, Change: -0.05, Percent Change: -0.87 ...

Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer

May 24, 2024

08:25 AM EDT, 05/24/2024 (MT Newswires) -- Verastem Oncology (VSTM) late Thursday reported that an ongoing phase 1/2 clinical trial evaluating avutometinib and defactinib in combination with gemcitabine and nab-paclitaxel in 41 patients with metastatic pancreatic cancer reached an interim partial response rate of 83%. Of 26 patients in all the trial cohorts who have had their first scan while...

Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation

May 24, 2024

08:17 AM EDT, 05/24/2024 (MT Newswires) -- Organon (OGN) and Shanghai Henlius Biotech said Friday their marketing authorization applications for HLX14, a denosumab biosimilar, have been validated by the European Medicines Agency. The submissions were based on a phase 3 study comparing HLX14 with denosumab in postmenopausal women with osteoporosis, the companies said. Henlius licensed HLX14 to Organon in 2022...